Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Gland and Hormone Related Diseases

Nutritional and Metabolic Diseases

Neoplasms

Rare Diseases

Syndrome

Hypertension

Cushing Syndrome

Metabolic Syndrome

Adrenocortical Adenoma

Adrenal Gland Neoplasms

Adenoma

Adrenal Cortex Neoplasms

Endocrine Gland Neoplasms

Adrenal Cortex Diseases

Adrenal Gland Diseases

Endocrine System Diseases

Cushing's Syndrome

Adenoma of the Adrenal Gland

Anti-Inflammatory Agents

All Drugs and Chemicals

Vasoconstrictor Agents

Respiratory System Agents

Antihypertensive Agents

Channel Blockers

Vasodilator Agents

Natriuretic Agents

Hydrocortisone

Hydrocortisone 17-butyrate 21-propionate

Hydrocortisone acetate

Hydrocortisone hemisuccinate

Epinephrine

Amlodipine

Spironolactone

Angiotensin Receptor Antagonists

Angiotensin II

Giapreza

Angiotensinogen

Racepinephrine

Epinephryl borate

Prazosin

Enzyme Inhibitors

Angiotensin-Converting Enzyme Inhibitors

Bisoprolol

Diltiazem

Indapamide

Adrenergic Agents

Adrenergic alpha-Agonists

Adrenergic Agonists

Neurotransmitter Agents

Adrenergic beta-Agonists

Bronchodilator Agents

Anti-Asthmatic Agents

Mydriatics

Sympathomimetics

Laparoscopic surgical removal of the adrenal tumor

Standardized medical treatment of hypertension by SAHR.

Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:

* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )
* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)
* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg
* step 4: Add-on of Indapamide LP 1.5 mg
* step 5: Add-on of Spironolactone 25 mg
* step 6: Add-on of Bisoprolol 10 mg
* step 7: Add-on of Prazosine LP 5mg/day.

Standardized medical treatment of hypertension by SAHR

Eric FRISON, Dr

The general objective is to evaluate the consequences of surgical removal of SCSI on hypertension and cardiovascular risk factors in order to determine on an evidence-based basis if surgical excision of SCSI is preferable to an intensive medical regimen in patients with hypertension.

Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With the widespread use of computed tomography and MRI, adrenal incidentalomas are found in approximately 2% of patients. In an endocrinology setting, the majority of these masses are benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display little excess of cortisol secretion associated to some degree of secretory autonomy but that are insufficient to generate overt Cushing's syndrome ("Subclinical Secreting Cortisol incidentalomas" or SCSI). However, hypertension and to a lesser degree obesity and impaired glucose tolerance are very frequent amongst patients with SCSI. The hypothesis that the mild hypercortisolism associated with SCSI is responsible for these clinical consequences is substantiated by few studies describing improvement after resection of SCSI. However, these studies were retrospective, uncontrolled and suffered from imprecision and numerous methodological bias. Thus, whether surgery is more beneficial than medical treatment is currently unknown and there is no consensus on the appropriate treatment for SCSI.

Patient selection Run-In period. Discontinuation of previous antihypertensive treatments and prescription of a standardized anti-hypertensive drug regimen (SAHR). Monthly Blood Pressure (BP) measurement using home BP monitoring. The duration of the Run-In periods will be ≤ 6 months and will end when BP will be controlled with the SAHR at two consecutive visits.

End of RI Second endocrine assessment for eligibility Randomization (Ra): 24h Ambulatory BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition questionnaires. Randomization in 2 groups : Gr 1 Treatment group : Surgery followed by intensive medical care ; Gr 2 : Control Group : intensive medical care only.

Ra + 1Mo: Surgery in Group 1 Ra + 2.5 Mo to Ra + 13 Mo: 6 weeks interval follow-up Evaluation of home BP monitoring and adaptation of the SAHR. A step by step reduction of the SAHR will be attempted in the two patient groups at Ra+2.5Mo. A second attempt will systematically be performed in both groups at Ra+8.5 Medical evaluation of associated metabolic conditions (obesity, diabetes, dyslipidemia) and adaptation of treatments Record of medical events and side effects of treatments Ra + 13Mo: Final evaluation. Endocrine assessment. 24h Ambulatory BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition questionnaires.

Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas

Treatment response will defined as a reduction of at least 1 step of SAHR at the end of the study, with BP maintained within the study objectives (\<135 mm Hg systolic and \<85 mm Hg diastolic) according to self-measurement at home.

age, family history of hypertension, duration of hypertension, kidney function, biochemical endocrine abnormalities, urinary steroid profile

Comparison of the two therapeutic strategies with regard to cardiovascular risk factors/markers: BMI, body composition evaluated by DEXA, abdominal fat evaluated on CT-scan, fasting blood glucose and insulin, HbA1C, HOMA-IR (homeostasis model of assessment of insulin resistance) and OGTT (oral glucose tolerance test), blood lipids, pro-inflammatory adipokines

Comparison of the two therapeutic strategies with regard to quality of life

University Hospital, Bordeaux

Musculoskeletal Diseases

Diabetes Mellitus

Osteoporosis

Hypercholesterolemia

Obesity

Adrenocortical Hyperfunction

Hyperadrenalism

Surgery to remove tumor when enrolled in the protocol.

Adrenalectomy

Observation for 6 months prior to surgery

Observation

Dhaval T Patel, M.D.

Background:

- Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases. Some people with extra cortisol will show symptoms like bruising and muscle weakness. Others will show no signs. This is called subclinical hypercortisolism. Some of these adrenal tumors become malignant. Researchers want to know the best way to treat people with subclinical hypercortisolism. They want to know if removing the tumor by surgery reduces the long-term effects of the disease.

Objectives:

- To see if removing an adrenal tumor by surgery improves blood pressure, diabetes, obesity, osteoporosis, or cholesterol, and cancer detection.

Eligibility:

- Adults 18 and older with an adrenal tumor and high cortisol levels.

Design:

* Participants will be screened with medical history, blood tests, and a computed tomography (CT) scan.
* Participants will have a baseline visit. They will have blood and urine tests and 7 scans. For most scans, a substance is injected through a tube in the arm. Participants will lie still on a table in a machine that takes images.
* Participants will have surgery to remove their tumor. Some will have surgery right away. Some will have surgery 6 months later, after 2 follow-up appointments.
* Participants will have 4 follow-up visits in the first year after surgery. They will have 2 visits the second year, then yearly visits for 3 years. At each follow-up visit, they will have scans and blood tests.

Background:

* Adrenal incidentalomas are common and found in approximately 4-7% of the population.
* About 0.6 to 25% of patients with an adrenal incidentaloma are found to have subclinical hypercortisolism: 2.3% develop subclinical hypercortisolism during follow up and 0.6% develop clinical hypercortisolism during follow up.
* Subclinical hypercortisolism is defined as biochemical excess of cortisol without signs and symptoms of overt hypercortisolism but may be associated with metabolic complications or disease progression and malignancy.
* Overt signs and symptoms of hypercortisolism include facial plethora, easy bruising, violaceous striae, and proximal muscle weakness.
* Several studies suggest that subclinical hypercortisolism may lead to long term consequences such as diabetes, hypertension, hypercholesterolemia, obesity, and osteoporosis.
* Thus, patients with subclinical hypercortisolism may benefit from operative intervention to halt or reverse metabolic complications associated with the disease and the risk of malignant progression.
* The optimal management of patients with subclinical hypercortisolism and adrenal incidentalomas is controversial and no large randomized trial has been conducted.
* We hypothesize that operative treatment would reduce the risk of long term complications of subclinical hypercortisolism and malignant progression, and propose a prospective randomized trial comparing nonoperative and operative management of subclinical hypercortisolism in patients with an adrenal neoplasm.

Objectives:

Primary Endpoints:

-To determine whether unilateral adrenalectomy in patients diagnosed with subclinical hypercortisolism and adrenal neoplasm results in normalization and/or improvement of hypertension as assessed by reduction in pharmacotherapy and/or normalization of blood pressure (systolic pressure \<=140 and diastolic pressure \<=90), diabetes as assessed by reduction or elimination of pharmacotherapy and/or improvement in A1C to \<6.5%, osteoporosis by increase in bone formation markers indicative of increased bone formation, hypercholesterolemia as assessed by a reduction or elimination of pharmacotherapy and/or reduction in low density lipoprotein (LDL) levels to risk-stratified goal levels as defined by Adult Treatment Panel III (ATP III), and/or overweight or obesity as assessed by a 10 percent reduction in weight at 6 months.

Eligibility:

* An individual with an adrenal neoplasm less than 5 cm in size with biochemically confirmed evidence of hypercortisolism (2 out of 3: dexamethasone suppression test (DST) \>3 mcgl/dL, elevated urine free cortisol, and/or morning adrenocorticotrophic hormone (ACTH) \<2.2 pmol/l) without overt clinical signs and symptoms.
* Age greater than or equal to 18 years.
* Adults must be able to understand and sign the informed consent document.
* Patients must have laboratory and physical examination parameters within acceptable limits based on standard clinical practice.

Design:

* Prospective randomized study comparing adrenalectomy versus observation.
* Patients assigned to the operative arm will undergo adrenalectomy and then followed postoperatively for normalization and/or improvement of metabolic complications associated with hypercortisolism and histologic examination of the resected tumor.
* Patients assigned to the non-operative arm will be monitored for possible complications associated with hypercortisolism for six months, at which point they will cross-over to the operative intervention arm.
* Patients with bilateral adrenal neoplasms will have the larger adrenal neoplasm used as the primary lesion responsible for subclinical hypercortisolism.
* Demographic, clinical, laboratory and pathologic data will be collected for each patient participant. Data will be securely stored in a computerized database.
* Patients will have biochemical testing to determine if their adrenal neoplasm is functioning or nonfunctioning.
* Projected accrual will be 15 to 20 patients per year for a total of 5 years. Thus, we anticipate accruing 62 patients on this protocol.

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Normalization and/or improvement of metabolic complications including hypertension, diabetes, osteoporosis, hypercholesterolemia and/or obesity after adrenalectomy is defined as 35% of patients who improve with surgery versus 5% who do not have surgery.

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Patients who were tested for and found to have adrenal cancer after adrenalectomy.

Proportion of patients who were diagnosed with subclinical hypercortisolism by FDG/PET/CT scan.

An assessment of whether 1 mg dexamethasone suppression test, basal adrenocorticotropic hormone (ACTH), midnight salivary cortisol, or urinary free cortisol is the optimal test to diagnose patients with subclinical hypercortisolism.

QOL questionnaires were provided to participants to assess well being pre and post operatively. Participants take a self-administered questionnaire to assess physical and mental health according to Cushing's Quality of Life Questionnaire. The score has a minimum of 12 and maximum of 60. A higher score indicates an improved quality of life.

Proportion of patients that developed deep venous thrombosis with subclinical hypercortisolism regardless of whether the participants received adrenalectomy or not.

A skin biopsy and skin ultrasound were done to measure the dermal layer of skin to look for a decrease in the thickness of skin as compared to normal values reported in the literature as measured in millimeters of thickness. Diagnostic sensitivity and changes in skin thickness were assessed.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Clinical Center Office of the Associates Director for Radiologic&Imaging Sciences

National Cancer Institute (NCI)

Principal Investigator

No toxicities were experienced by any participants on this trial.

operative arm

Adrenalectomy: Surgery to remove tumor when enrolled in the protocol.

Operative Arm

delayed operative arm

Observation: Observation for 6 months prior to surgery

Delayed Operative Arm

Delayed Operative Arm Followed by Surgery

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Dr. Dhaval Patel

Proportion of Patients That Have Normalization and/or Improvement of Metabolic Complications After Adrenalectomy

Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)

Proportion of Patients Who Are Found to Have Adrenal Cancer After Adrenalectomy

Proportion of Patients Who Were Diagnosed With Subclinical Hypercortisolism by Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) Scan

This outcome measure was not done. Data was collected and not analyzed because we were not able to determine the optimal test since we only had four patients enrolled, and three patients on study (e.g. low accrual). Therefore, we couldn't do a head to head comparison calculating the sensitivity and specificity.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas	NCT02364089	Adrenal Inciden...	Laparoscopic su... Standardized me...	18 Years - 80 Years	University Hospital, Bordeaux
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism	NCT02001051	Subclinical Hyp... Cushing Syndrom... Adrenal Neoplas...	Adrenalectomy Observation	18 Years - 99 Years	National Institutes of Health Clinical Center (CC)
Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas	NCT02364089	Adrenal Inciden...	Laparoscopic su... Standardized me...	18 Years - 80 Years	University Hospital, Bordeaux

Spots Global Cancer Trial Database for adrenal incidentalomas